Is Infinium Pharma overvalued or undervalued?

As of 5 September 2025, the valuation grade for Infinium Pharma has moved from attractive to fair, indicating a shift in market perception. The company is currently fairly valued, with a PE ratio of 46.90, an EV to EBITDA of 26.19, and a ROCE of 21.16%. In comparison to its peers, Sun Pharma has a PE ratio of 33.33 and an EV to EBITDA of 22.53, while Cipla stands at a more attractive PE of 23.25 and an EV to EBITDA of 16.37.
Despite the fair valuation, Infinium Pharma has seen a decline in stock performance, with a year-to-date return of -16.64% compared to a positive 4.64% return for the Sensex. This underperformance may suggest that the market is reassessing the growth prospects of the company relative to its peers, particularly in a competitive pharmaceutical landscape.